48,597
edits
(→IHC) |
|||
(13 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
''Foregut primary'' directs to this article. | ''Foregut primary'' directs to this article. | ||
==Foregut== | |||
The foregut includes the following: | |||
*[[Esophagus]]. | |||
*[[Stomach]]. | |||
*[[Duodenum]], proximal portion - to the ampulla of Vater. | |||
*[[Liver]]. | |||
*[[Gallbladder]]. | |||
*[[Pancreas]].<ref name=pmid23630303>{{cite journal |authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA |title=Development of the human pancreas from foregut to endocrine commitment |journal=Diabetes |volume=62 |issue=10 |pages=3514–22 |date=October 2013 |pmid=23630303 |pmc=3781486 |doi=10.2337/db12-1479 |url=}}</ref> | |||
*Lower respiratory tract. | |||
==IHC== | |||
Foregut carcinomas are typically: | |||
*CK7 +ve. | |||
*CK20 -ve. | |||
*CDX2 -ve. | |||
*[[HNF-1beta]] +ve (72-87% of cases +ve in one study<ref name=pmid30065837>{{cite journal |authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref>). | |||
A (query) foregut primary panel for liver lesions: | |||
*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1. | |||
==See also== | ==See also== |
edits